Form 4: Centessa Pharmaceuticals CEO Saurabh Saha Sells Shares Under 10b5-1 Trading Plan

Centessa Pharmaceuticals CEO Saurabh Saha sold 55,000 ordinary shares at an average price of $16.527 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 20, 2024, Saurabh Saha, CEO of Centessa Pharmaceuticals plc, sold 55,000 ordinary shares of the company.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 16, 2024.
• The shares were sold at prices ranging from $16.28 to $16.73, with a weighted average price of $16.527.
• Following the transaction, Saha directly owns 721,924 ordinary shares and indirectly owns 38,000 shares through a trust.
• Saha and his spouse serve as trustees for the trust holding the indirectly owned shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting the sale of shares by the CEO. It is neutral in tone and does not inherently indicate positive or negative sentiment about the company's prospects. The sale was conducted under a pre-arranged trading plan.

Industry Context

Sales by insiders are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are generally viewed as less informative.

Key Dates